Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

The upfront and near-term payment, backed by milestones that could take the total value of the licensing deal to around ... scalability," he said. Novo Nordisk and Septerna will jointly carry ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by ...

Read on for a whirlwind, worldwide tour of recent personnel moves. A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates ...

Novo Nordisk is teaming up with Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.